ApoO FOR USE IN A METHOD FOR TREATING CANCER AND VARIOUS PATHOPHYSIOLOGICAL SITUATIONS

Abstract

The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to a compound for use for treating a pathophysiological situation, wherein said compound is an inhibitor of the ApoO activity or of the ApoO gene expression.

1 - 18 . (canceled) 
     
     
         19 . A method for inducing apoptosis in a cancerous cell comprising a step of administering, in an effective amount to induce apoptosis of said cancerous cell, an expression vector comprising a nucleic acid encoding a compound selected from the group consisting of Apolipoprotein O (ApoO) or encoding a polypeptide comprising an ApoO fragment which induces apoptosis comprising at least one of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 or mixtures thereof. 
     
     
         20 . The method according to  claim 19 , wherein said method is for treating cancer. 
     
     
         21 . A method according to  claim 19 , wherein said cancerous cell is selected from the group consisting of heart cell, liver cell, bladder cell, brain cell, breast cell, colon cell, rectum cell, endometrium cell, kidney cell, blood cell, epidermis cell, pancreas cell, prostate cell and thyroid cell. 
     
     
         22 . A method according to  claim 19 , wherein said cancerous cell is a brain cancer cell, said brain cancer being selected from brain cancers includes chordomas, craniopharyngiomas, gangliocytomas, gangliomas, anaplastic gangliogliomas,  glomus  jugulare, meningiomas, pineocytomas, pituitary adenomas, schwannomas, glioma, hemangioblastomas and rhabdoid tumors. 
     
     
         23 . A method according to  claim 19 , wherein said cancerous cell is selected from the group consisting of astrocytes, ependymal cells and oligodendroglial cells. 
     
     
         24 . A method according to  claim 19 , wherein said cancer is glioblastoma. 
     
     
         25 . A method according to  claim 19 , wherein said compound is a human ApoO as depicted in SEQ ID NO: 1. 
     
     
         26 . A method according to  claim 19 , wherein said compound is said polypeptide comprising an ApoO fragment, said fragment having a length between 30 to 190 amino acids. 
     
     
         27 . The method according to  claim 26 , wherein said polypeptide has a length between 50 and 130 amino acids. 
     
     
         28 . The method according to  claim 27 , wherein said polypeptide has a length between 70 and 120 amino acids. 
     
     
         29 . A method according to  claim 19 , wherein said compound is said polypeptide comprising an ApoO fragment, said fragment having a length between 8 and 190 amino acids. 
     
     
         30 . The method according to  claim 29 , wherein said polypeptide has a length between 8 and 100 amino acids. 
     
     
         31 . The method according to  claim 30 , wherein said polypeptide has a length between 8 and 50 amino acids. 
     
     
         32 . A method according to  claim 19 , wherein said compound is ApoO or a fragment thereof comprising at least one of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12. 
     
     
         33 . The method according to  claim 19 , wherein said compound consists of SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12. 
     
     
         34 . A method according to  claim 19 , wherein said compound is the fragment of ApoO depicted in SEQ ID NO: 12. 
     
     
         35 . A method according to  claim 19 , wherein said compound interacts with mitochondrial permeability transition pore (MPTP), driving MPTP to adopt an open state hereby inducing mitochondrial uncoupling. 
     
     
         36 . A method according to  claim 19 , wherein said compound interacts with Cyclophillin D (CyPD) or adenine nucleotide translocase (ANT). 
     
     
         37 . A method according to  claim 19 , wherein said compound increases mitochondrial respiration, increases fatty acid metabolism and induces lipid accumulation within said cancerous cells. 
     
     
         38 . The method according to  claim 19 , wherein said expression vector is a plasmid, a cosmid or a phage. 
     
     
         39 . The method according to  claim 19 , wherein said expression vector is a viral vector. 
     
     
         40 . The method according to  claim 39 , wherein said viral vector is an oncoretroviral vector or a lentiviral vector. 
     
     
         41 . The method according to  claim 19 , wherein said expression vector is an adeno associated virus (AAV). 
     
     
         42 . The method according to  claim 19 , wherein said expression vector is an AAV chosen in the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 and AAV11. 
     
     
         43 . The method according to  claim 19 , wherein said expression vector is an AAV9.